In-market Utilisation of Liraglutide Used for Weight Management in Europe

Novo Nordisk

Status: Completed

Conditions: Metabolism and Nutrition Disorder; Obesity

Treatments: Drug: liraglutide

Study type: Observational

Funder types: Industry

Identifiers

NCT02967757

U1111-1185-3661 (Other Identifier)

EUPAS16225 (Registry Identifier)

NN8022-4241

Details and patient eligibility

About

This study is conducted in Europe. The aim of this study is to investigate usage of liraglutide for weight management in clinical practice.

Enrollment: 316 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Initiation of liraglutide 3.0 mg / liraglutide 1.2 mg/1.8 mg (initiation is defined as no prescription of the same brand within the previous 12 months)
• Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability of the study

Exclusion criteria

-Patients or physicians who previously participated in interventional studies for liraglutide 3.0 mg / liraglutide 1.2 mg/1.8 mg will not be eligible to participate in the study -For the full study, sites and patients included in the pilot will be excluded

Trial design

316 participants in 1 patient group

liraglutide 3.0 mg / liraglutide 1.2 mg/1.8 mg

Treatment:

Drug: liraglutide